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Abstract
Background: It is sometimes difficult to distinguish between premature thelarche and precocious
puberty in girls who develop breasts before the age of 8 years. We evaluated the frequencies of
the signs associated with breast development and the factors influencing the presentation of girls
with idiopathic central precocious puberty (CPP).
Methods: 353 girls monitored 0.9 ± 0.7 year after the onset of CPP.
Results: The age at CPP was < 3 years in 2%, 3–7 years in 38% and 7–8 years in 60% of cases. Pubic
hair was present in 67%, growth rate greater than 2 SDS in 46% and bone age advance greater than
2 years in 33% of cases. Breast development was clinically isolated in 70 (20%) cases. However, only
31 of these (8.8% of the population) had a prepubertal length uterus and gonadotropin responses
to gonadotropin releasing hormone and plasma estradiol. The clinical picture of CPP became
complete during the year following the initial evaluation.
25% of cases were obese. The increase in weight during the previous year (3.7 ± 1.4 kg) and body
mass index were positively correlated with the statural growth and bone age advance (P < 0.0001).
There was no relationship between the clinical-biological presentation and the age at puberty, the
interval between the onset of puberty and evaluation, or the presence of familial CPP.
Conclusion: The variation in presentation of girls with CPP does not depend on their age, interval
between the onset and evaluation, or familial factors. This suggests that there are degrees of
hypothalamic-pituitary-ovarian activation that are not explained by these factors.
Background
Precocious puberty in girls is defined by the development
of sexual characters before the age of 8 years. Precocious
breast development is usually due to the premature acti-
vation of the hypothalamo-pituitary-ovarian axis, defin-
ing central precocious puberty (CPP) [1]. It is rarely of
ovarian [2] or adrenal origin. It may also correspond to
premature thelarche, which is defined by non-pathologi-
cal isolated early breast development – generally during
the first two years of life [1].
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It can be difficult to distinguish CPP from premature the-
larche, as CPP may present as isolated breast development
and girls with premature thelarche may be older or have
early puberty [3,4]. Isolated thelarche is ruled out on the
basis of progressive secondary sexual development and
accelerated growth and skeletal maturation.
CPP in girls is idiopathic in the majority of cases [5,6]. All
the girls with CPP and organic intracranial lesions were
either less than 6 years old or had a plasma estradiol con-
centration above the 45th percentile [7]. New guidelines
propose that girls who develop breasts or pubic hair
before the age of 7 (white girls) or 6 years (African-Amer-
ican girls) should be evaluated [8]. The factors contribut-
ing to the earlier onset of puberty are probably genetic [9]
and/or environmental, particularly obesity [5,10,11]. We
analyzed the clinical-biological presentation of 353 girls
with idiopathic CPP in order to evaluate the frequencies
of the signs associated with breast development and the
factors influencing the presentation of CPP.
Methods
Patients
This retrospective study was carried out on 353 consecu-
tive girls monitored by one of us (R Brauner) for idio-
pathic CPP from June 1984 to February 2006. They were
seen in a tertiary university pediatric hospital, one of the
5 referral centers for pediatric endocrinology in the Assist-
ance Publique Hôpitaux de Paris. CPP was diagnosed on
the appearance of breast development before the age of 8
years accompanied by the presence of one or more of the
following: pubic or axillary hair, growth rate greater than
2 SDS or bone age greater than 2 years above chronologi-
cal age [9]. Patients with isolated breast development were
followed for at least 6 months before diagnosis was made.
Organic intracranial lesions were excluded by neuroradio-
logical evaluation in all cases, as were ovarian and adrenal
disorders. The interval between the onset of puberty and
the initial evaluation was 0.9 ± 0.7 year.
Methods
Written informed consent for the evaluation was obtained
from the parents. Familial CPP was defined by the moth-
ers having undergone menarche (available in 295 of
them) before the age of 10 or 11 years.
The initial evaluation included determinations of height,
weight, pubertal stage, bone age, pelvic ultrasound (n =
152) and evaluation of the hypothalamic-pituitary-ovar-
ian axis by measuring basal and gonadotropin releasing
hormone (GnRH, 100 μg/m2; maximum dose 150 μg)-
stimulated luteinising hormone (LH) and follicle stimu-
lating hormone (FSH) peaks, and the plasma concentra-
tion of estradiol. The adrenarche was evaluated by the
plasma concentrations of dehydroepiandrosterone sulfate
(DHAS, n = 115). Plasma 17-hydroxyprogesterone and
testosterone concentrations were measured in those girls
whose first sign was pubic hair development to exclude
abnormal androgen secretion. Plasma thyroxin and thy-
roid stimulating hormone concentrations were measured
in those who were overweight to exclude hypothyroidism
and 24 h urinary cortisol was measured to exclude hyper-
cortisolism.
Height, growth rate and body mass index (BMI, weight in
kg/height in m squared) are expressed as SDS for chrono-
logical age [12,13]. The pubertal stage was rated according
to Marshall and Tanner [14]. Bone age was assessed by
one of us by the Greulich and Pyle method [15]. Plasma
LH, FSH and estradiol concentrations were measured
using different immunoassays during the study period.
When the assay method for a given hormone was
changed, it was cross-correlated with the previous
method. Thus, the results for a given parameter are com-
parable throughout the whole period. The values consid-
ered to be pubertal were: uterus length of ≥ 35 mm [16],
LH/FSH peaks ratio after GnRH test ≥ 0.66 [17], and
plasma estradiol concentrations ≥ 15 pg/mL (55 pmol/L).
Data are expressed as means ± SD. Groups were compared
with the Kruskall Wallis test followed by a Mann-Whitney
U test. Correlations were analyzed using Spearman's test.
Results
1. Presentation
The characteristics of the patients and the percentages of
increased values are shown in Table 1 and Fig 1 and 2. The
age at onset of CPP was less than 3 years in 7 patients
(2%), but their characteristics (Table 2) were similar to
those of the others. It was 3–7 years in 133 (38%) patients
and 7–8 years in 213 (60%).
Breast development was stage 2 in 47% of cases and
greater in the others. This development was isolated in 70
(20%) cases and associated with other clinical signs sug-
gesting CPP in the remainder.
Of the 70 patients with isolated breast development, 39
were diagnosed as having CPP at presentation, with a
uterus length of ≥ 35 mm (16/31), a LH/FSH peaks ratio
of ≥ 0.66 (25/68) and/or plasma estradiol concentrations
≥ 15 pg/mL (18/67). The clinical picture of CPP in the
other 31, aged 3.2–7.9 years, became complete during the
year following the initial evaluation. They were compared
to those with other signs at presentation: their ages at
puberty were similar, as were the intervals between the
onset of puberty and the initial evaluation, but their BMIs
were lower (0.9 ± 1 SDS; others 1.3 ± 1.4 SDS, P < 0.05),
their weight increased less during the previous year (3 ±
1.2 kg; 3.9 ± 1.4 kg, P < 0.0001), their plasma estradiolBMC Pediatrics 2008, 8:27 http://www.biomedcentral.com/1471-2431/8/27
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concentrations were lower (14 ± 13 pg/mL; 20 ± 17 pg/
mL, P < 0.004), as were their LH peaks (7.1 ± 7.2 IU/L;
12.2 ± 15.1 IU/L, P < 0.02) and LH/FSH peaks ratios (0.5
± 0.5; 0.9 ± 0.9, P < 0.005).
The pubic hair development was stage 1 (n = 120, 33%),
stage 2 (n = 130) or greater (n = 103). The ages at puberty
and at presentation and the BMIs of girls without pubic
hair development were similar to those with stage P2, but
their bone age was less advanced (0.8 ± 1.1; P2 1.3 ± 1.3
years, P < 0.006). Those with a lower BMI had a lower
DHAS (357 ± 259 ng/mL) than those with a BMI greater
than one SDS (481 ± 344 ng/mL, P < 0.03).
The increase in weight during the previous year (3.7 ± 1.4
kg, n = 267) was positively correlated with the height and
bone age advance (P < 0.0001 for all), but not with estra-
diol, LH peak, or the LH/FSH peaks ratio. The bone age
advance was positively correlated with the BMI, statural
growth rate and estradiol (P < 0.0001 for all).
2. Presentation factors
The characteristics of the patients (Table 1) were com-
pared according to their age at puberty, the interval
between the onset of puberty and evaluation, BMI and the
presence of familial CPP. The patients aged 3–7 years were
taller (2.2 ± 1.4 SDS) than those aged 7–8 years (1.9 ± 1.2
SDS, P < 0.01), while their bone age advance was similar.
When the patients were classified according to whether
the interval between the onset of puberty and evaluation
was greater than or less than 0.9 year (mean interval),
there was no difference in their characteristics. When they
were classified according to their BMI (below or above 2
SDS, 25.3%), those with the lower BMI were shorter (1.9
± 1.3 SDS; higher BMI 2.5 ± 1.3 SDS, P < 0.0001). The dif-
ference was similar with a limit of BMI at the mean. When
they were classified according to the year of presentation
(intervals of 5 years from 1984 to 2006), the BMI (SDS)
varied from 1.1 ± 1.5 (n = 48) in the oldest, to 1.5 ± 1.5 (n
= 51), 1.3 ± 1.2 (n = 125) and 1.0 ± 1.4 (n = 127) in the
youngest.
The age at menarche of the mothers was < 10 years in 4%
and < 11 years in 27% of cases. Their characteristics, and
those of the 5% who were adopted, were similar to those
of the others.
Discussion
We have assessed the frequencies of the signs associated
with breast development in 353 consecutive girls with idi-
opathic CPP. This development was associated with other
signs in 91.2% of cases at presentation, leading to the
immediate exclusion of premature thelarche. One quarter
of the girls were obese.
1. Diagnosis at presentation
The distribution of ages at onset of puberty was similar to
that reported in a multicenter study on 428 girls with CPP,
including 56 with organic CPP [6]. In this study, as in
ours, the age at onset of CPP was 7–8 years in 60% of
cases. The clinical-biological features of these patients
were similar to those of the younger ones, except for their
height. This emphasizes the difficulty of deciding on the
age limit leading to an evaluation. Growth rate was greater
than 2 SDS in 45.8% and height ≥ 2 SDS in 54% of the
cases at presentation. Papadimitriou et al [18] showed
that the growth rate of girls with idiopathic CPP acceler-
ates soon after birth, reaches a zenith centile in the first 2
to 4 years of life, then continues along this centile until
they enter puberty, usually between 6 and 8 years, when
growth again accelerates.
The association of CPP with overweight or a rapid increase
in weight is a difficult confounding factor; it may contrib-
ute to the earlier onset of puberty (see below), but may
Table 1: Presentation of 353 girls with idiopathic CPP.
n m ± SD range increased values
n%
Age at onset, years 353 6.7 ± 1.3 0.5/8.0
Age at evaluation, years 353 7.6 ± 1.4 0.75/9.7
Height, SDS 353 2.1 ± 1.3 -3.0/6.2 ≥ 2SD 191 54
Growth rate, SDS 319 2.3 ± 2.0 0/9.8 ≥ 2SD 145 45.8
BMI, SDS 351 1.2 ± 1.3 -2.7/4.7 ≥ 2SD 89 25.3
Bone age advance, years 348 1.3 ± 1.3 -2.0/6.0 ≥ 2 years 114 32.7
Uterus length, mm 152 35.2 ± 8.4 17/64 ≥ 35 mm 83 54.6
Estradiol, pg/mL 344 18 ± 16 2/100 ≥ 15 pg/mL 138 40.1
LH peak, IU/L 348 11.2 ± 14.1 0.3/101 ≥ 15 IU/L 85 24.4
FSH peak, IU/L 348 13.2 ± 7.5 0.8/62
LH/FSH peaks ratio 348 0.8 ± 0.88 0.05/5.7 ≥ 0.66 151 43.3BMC Pediatrics 2008, 8:27 http://www.biomedcentral.com/1471-2431/8/27
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also be a symptom of an intracranial lesion. Among the
11 girls with a CPP-revealing lesion, puberty began at 7–8
years in 2 girls having an optic glioma with its risk of
blindness [19]. Midyett et al [20] reported that signs of
puberty at 6–8 years should not be considered normal or
benign, and that implementation of the new guidelines
for evaluating puberty will result in failure to identify con-
ditions that respond to early intervention.
Breast development was clinically isolated in 70 (20%)
cases. However, only 31 (8.8%) had a prepubertal length
of uterus, gonadotropin responses to GnRH test and
plasma estradiol concentrations. The clinical picture of
CPP became complete during the year following the ini-
tial evaluation. It was difficult to differentiate between
premature thelarche and CPP at presentation in these
cases. This differentiation is easy in a girl aged less than
two years who presents with isolated breast development,
frequently following neonatal breast development. How-
ever, breast development may be associated with light
pubic hair development in a few of these cases. This is
probably due to the neonatal period gonadotropins peak.
In this situation, pubic hair development is associated
with increases in the plasma concentrations of delta 4
androstenedione, but not that of DHAS, suggesting that it
is of ovarian rather than adrenal origin [21]. Pescovitz and
al [22] speculated that premature thelarche and CPP may
be different positions along a continuum of hypothalamic
GnRH neuron activation. The baseline evaluation of girls
with premature thelarche who progressed during follow-
up to early puberty established no characteristics that sep-
arated them from those who did not progress [3]. A com-
parison of the frequencies of premature thelarche and of
precocious or early puberty showed different results.
Kaplowitz et al [23] studied 104 children consecutively
referred over a 3 year period for signs of early puberty, and
found that the two most common diagnoses were prema-
ture adrenarche (46%) and thelarche (18%), while only
9% had CPP. This differs from the data published by de
Vries et al [9], who reported that more than half of the 453
children they studied had either idiopathic CPP or early
puberty. These authors suggested that the difference
between the two studies could be due to the fact that all of
their patients were followed for a minimum of 2 years,
and that the diagnoses were deferred for at least 6 months
when the clinical picture was not clear [24].
Percentages of pubic hair development, increased growth rate and bone age advance in 353 girls with idiopathic CPP Figure 1
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Distribution of the LH and FSH peaks and LH/FSH peaks ration after GnRH test in 348 girls with idiopathic CPP Figure 2
Distribution of the LH and FSH peaks and LH/FSH peaks ration after GnRH test in 348 girls with idiopathic 
CPP.BMC Pediatrics 2008, 8:27 http://www.biomedcentral.com/1471-2431/8/27
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The development of pubic or axillary hair is the most fre-
quent clinical sign associated with breast development,
occurring in 67% of cases. The uterus length was ≥ 35 mm
in 54.6% of the cases evaluated. De Vries et al [16] com-
pared girls with CPP to girls with premature thelarche and
showed that bone age SDS, uterine transverse diameter,
and uterine volume were the most significant variables
predicting CPP.
In the girls with precocious breast development, the
increases in the LH and FSH plasma concentrations in
response to a GnRH test excludes a peripheral origin, as
we observed during the study period in two patients with
ovarian granulosa cell tumor [2], in five patients with
McCune-Albright syndrome and in 11 with isolated ovar-
ian cyst [25]. The criteria defining a pubertal response to a
GnRH test in girls are an LH peak greater than 15 IU/L (in
24.4% of our study) and an LH/FSH peaks ratio greater
than 0.66 (in 43.3%); these detected 96% of the pubertal
girls with no false positives [17]. We have shown that the
LH/FSH peaks ratio is significantly correlated with ante-
rior pituitary height in girls with idiopathic CPP [26].
Palmert et al [27] defined a prepubertal response as an
FSH peak greater than the LH peak and an LH peak of less
than 25 IU/L. The recently reported girl with CPP due to a
GPR54-activating mutation had an LH peak of 8.5 IU/L
and a plasma estradiol concentration of 13 pg/mL during
her initial evaluation [28]. The gonadotropin concentra-
tion also varies according to the assay used.
2. Presentation factors
We find no relationship between the clinical-biological
presentation and the age at puberty, the interval between
the onset of puberty and evaluation, or familial factors.
The increases in weight (3.7 ± 1.4 kg) and BMI during the
previous year are positively correlated with the statural
growth and bone age advance, but not with the estradiol,
LH peak, or with the LH/FSH peaks ratio.
Palmert et al [27] found that those girls with slowly pro-
gressing idiopathic CPP had lower BMIs than girls with
classical CPP (P < 0.02), as we found in those with iso-
lated breast development at presentation (P < 0.05).
Obesity is an important contributing factor to the earlier
onset of puberty in girls. De Simone et al [29] reported
that fat children grew faster than did the normal popula-
tion up to the age of 13 years (boys) and 12.5 years (girls),
while the heights of obese and non-obese subjects were
the same at 18 years. There is a positive correlation
between plasma insulin and height SDS. Klein et al [30]
reported that obese children were younger, taller, and had
more advanced bone maturation than non-obese children
at a similar pubertal stage, confirming the accelerated
bone maturation and relatively earlier puberty in obese
children. For given estradiol concentrations and bone
ages, obese children are significantly younger (chronolog-
ical age) than non-obese children. Davison et al [11]
showed that girls with a greater percentage of body fat,
BMI percentile, or larger waist circumference at 7 years
were more likely to have more advanced pubertal devel-
opment at 9 years. Lee et al [31] reported that a higher
BMI at 36 months, and a faster change in BMI between 36
months and the onset of puberty, are associated with an
earlier onset of puberty, as was an earlier age of menarche
in the mothers.
Only 4% of the mothers of our patients were aged less
than 10 years at menarche, while de Vries et al [9] found
familial factors in 42/147 (36%) girls with idiopathic
CPP. This is probably due to the fact that they made a
Table 2: Characteristics of 7 girls with idiopathic CPP beginning before 3 years
Patient 1 2 3 4 5 6 7
Age at onset, years 0.5 0.7 1.0 1.0 1.7 2.0 2.0
Age at evaluation, years 0.75 0.8 3.2 2.3 2.0 2.7 2.9
Height, SDS 1.0 1.0 2.5 0.9 2.8 2.1 1.8
Growth rate, SDS 3.3 0.1 2.4 1.8 0.4
BMI, SDS -0.84 0.2 0.44 -0.16 -0.91 3.9 0.12
Bone age advance, years 0.5 0.1 1.8 0.2 3.0 0.8 1.1
Uterus length, mm 27 NA NA 30 NA NA NA
Estradiol, pg/mL 9 100 50 9 30 15 5
LH peak, IU/L 3.1 52 34 2.6 17.4 23 3.6
FSH peak, IU/L 28 27 23.3 17 11.4 21.4 22
LH/FSH peaks ratio 0.11 2.0 1.4 0.15 1.5 1.1 0.16
GnRH analogue treatment yes yes yes yes yes yes no
Familial CPP NA NA no yes NA no no
Final height, SDS NA NA 0.0 NA NA -1.1 NA
Pubic hair development in all cases
Patients 1 and 4 were treated because of progression of their puberty.BMC Pediatrics 2008, 8:27 http://www.biomedcentral.com/1471-2431/8/27
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wide familial analysis, not limited to the maternal age at
menarche. We did not collect data on the pubertal matu-
ration of the fathers. We agree with their suggestion that
some familial cases are missed by excluding patients with
pubertal onset between 8 and 10 years, or with early fast
puberty. Like them, we find no difference in the BMI, sug-
gesting that familial obesity is not a cause of familial CPP.
Conclusion
The variation in presentation of girls with idiopathic CPP
does not depend on their age, interval between the onset
of puberty and evaluation, or familial factors. This sug-
gests that there are degrees of hypothalamic-pituitary-
ovarian activation that are not explained by these factors.
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